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Eﬃcacy of a Probiotic-Prebiotic Supplement on Incidence of
Diarrhea in a Dog Shelter: A Randomized, Double-Blind,
Placebo-Controlled Trial
L. Rose, J. Rose, S. Gosling, and M. Holmes
Background: Diarrhea is the most frequent morbidity aﬀecting kenneled dogs in animal shelters. Diarrhea impacts animal
welfare and the ﬁnances of the shelter as they must treat, clean, and house aﬀected animals until recovered.
Hypothesis/Objectives: Supplementing dogs entering an animal shelter with a probiotic-prebiotic, known as a synbiotic,
will decrease the incidence of diarrhea.
Animals: Seven hundred and seventy-three dogs entering an animal shelter in the United Kingdom.
Methods: A prospective double-blind, randomized, placebo-controlled trial.
Results: Statistical diﬀerence was found between the groups across 3 measures of diarrhea incidence. First, the mean per-
centage of scored days per dog that were scored as diarrhea throughout their stay was 2.0% in the synbiotic group and 3.2%
in the placebo group (P = .0022). Second, the occurrence of diarrhea within the ﬁrst 14 days’ stay was 18.8% in the synbiotic
product group and 27.2% in the placebo group (P = .0008). Third, the occurrence of ≥2 consecutive days of diarrhea within
the ﬁrst 14 days’ stay was 4.6% in the synbiotic product group and 8.0% in the placebo group (P = .0300).
Conclusions and clinical importance: Supplementing healthy dogs entering an animal shelter with a synbiotic supplement
signiﬁcantly decreased the incidence of diarrhea in this trial. Animal shelters can use synbiotic supplements to improve animal
welfare and decrease costs involved in cleaning and housing animals as well as potentially decreasing veterinary intervention.
Key words: Canine; Diarrhea and vomiting; Enterococcus faecium; Gastrointestinal; Gastroenterology; Nutrition.
Diarrhea is deﬁned as an increase in fecal water con-tent, which usually leads to changes in fecal volume,
ﬂuidity, and frequency of defecation.1 Kenneling
increases the likelihood of dogs developing diarrhea,2 and
diarrhea is reported as the most common disease of dogs
housed in animal shelters.3 Diarrhea has a direct negative
impact on the welfare of kenneled dogs and also may lead
to extended time periods in the animal shelter as aﬀected
animals cannot be rehomed until they are producing nor-
mal feces. In addition, there is a ﬁnancial burden on the
animal shelter resulting from delayed rehoming, veteri-
nary interventions, and additional cleaning.
Probiotics are live microorganisms that, when deliv-
ered in adequate amounts, confer a health beneﬁt to the
host.4,5 Prebiotics are ingredients selectively fermented
in the gastrointestinal tract to allow speciﬁc changes, in
the composition, activity, or both in the gastrointestinal
microbiota, conferring beneﬁts upon host well-being
and health.6 When a probiotic and a prebiotic are given
together, the combination is called a synbiotic, suggest-
ing a synergistic relationship between the 2. There are
several proposed mechanisms to the underlying antago-
nistic eﬀects of probiotics on various microorganisms,
including the following: modiﬁcation of the gut micro-
biota, competitive adherence to the epithelial mucosa,
strengthening of the gut epithelial barrier, and modula-
tion of the immune system to convey an advantage to
the host.7 These proposed probiotic mechanisms of
action could have a clinically relevant impact on treat-
ment and prevention of acute diarrhea.8
Two previous clinical trials have investigated the use of
probiotic supplementation for the prevention of diarrhea
in kenneled dogs. In 1 trial that used diﬀerent doses of
probiotic, signiﬁcantly fewer supplemented dogs passed
unacceptable (loose or diarrheic) feces in the ﬁrst week of
relocation to a kennel facility and during their total stay,
when compared to the control group.9 Another study
failed to obtain statistically signiﬁcant evidence to accept
their hypothesis that kenneled dogs fed a probiotic would
be less likely to have diarrhea of ≥2 days duration than
those given placebo,10 and this study frequently is refer-
enced in review articles about probiotics11–18 when dis-
cussing the eﬃcacy of probiotics on gastrointestinal
disease in dogs. Yet of the 182 dogs recruited in the trial,
only 2 (1 in each group) had diarrhea of ≥2 days’
duration.10 With this incidence of diarrhea in the placebo
group (1.25% of dogs), 18,608 dogs would have been
required to detect a 33% reduction in ≥2 days’ diarrhea,
with a signiﬁcance level of 0.05 and a power of 80%a.
Therefore, it is not possible to draw conclusions about
probiotic eﬃcacy in kenneled dogs from this trial because
of the low incidence of diarrhea.
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The aim of our study was to test the hypothesis that
prophylactic treatment of dogs in an animal shelter with
a synbiotic supplement would decrease the incidence of
diarrhea compared with a control group.
Materials and Methods
A prospective, randomized, double-blind placebo-controlled
trial was designed for dogs entering Wood Green, The Animals
Charity, Godmanchester, for which ethical approval was obtained
from the University of Cambridge Ethics and Welfare Committee
(reference CR93).
All dogs entering the animal shelter were considered for inclu-
sion in the trial. Animals were excluded if they left the shelter
before kennel assignment and randomization (i.e., strays that were
reclaimed by their owners). All dogs entering the shelter were
examined by a veterinarian, and all dogs with abnormal clinical
ﬁndings suggesting preexisting disease or with a history of chronic
or recurrent diarrhea were excluded from the trial (see Fig 1).
On admission to the animal shelter, dogs were housed in an iso-
lation block for 7–10 days before being moved to a main kennel-
ing site that could hold a maximum of 100 dogs. Dogs were fed
twice daily by a variety of donated foods or a prescribed diet if
the veterinarian deemed doing so necessary. During kennel assign-
ment, dogs were randomized to receive either synbiotic or placebo
capsules by taking a randomly selected colored plastic disc from
an opaque bag. The bag contained ﬁfty identical plastic discs with
equal numbers of 2 diﬀerent colors; each color assigned to a speci-
ﬁc group. Once a counter was selected, it was placed back in the
bag. When 2 dogs entered the shelter as a pair, they shared a ken-
nel and both animals were assigned to the same treatment group.
The synbiotic and placebo capsules were produced by Protexin
Veterinary and matched for color, size, texture, and packaging.
They were diﬀerentiated only by capsule A or capsule B printed
on the blister foil. The active capsule was a commercially available
product containing Enterococcus faecium NCIMB 10415 4b1707,
2 9 109 colony-forming units(cfu)/capsule, and 46.4 mg/capsule
Preplex prebiotic, a combination of fructo-oligosaccharide (FOS)
and acacia (gum arabic)b . The placebo contained 180 mg mal-
todextrin, a complex carbohydrate commonly used as an inert
additive. One capsule was opened and sprinkled on each dog’s
food once daily, at the evening meal. Supplementation began at
the ﬁrst evening meal after randomization and continued through-
out the dog’s stay. All staﬀ at the animal shelter and the monitor
were blinded to capsule contents. The unblinding key was held by
a third party with no other role in the trial.
Dogs had their fecal consistency score recorded on a daily
health sheet throughout the duration of their stay at the shelter.
Any results from the day of randomization were not included in
analysis because it was not possible to know whether these feces
were passed before or after the ﬁrst dose in the evening meal.
Before the trial started, staﬀ received training on how to score
feces either: hard, normal, soft, diarrhea, or no feces passed. The
score was attained by comparing the feces passed by the dog to a
scoring system with a descriptor and a representative picture:
Hard Hard. Dry and crumbly. Kickable.
Normal Well-formed. Firm but not hard. Easy to pick up.
Soft Shaped but wet feces. Lose their shape as they are
picked up.
Diarrhea Watery feces with no shape.
The softest fecal reading of the day’s feces was used as the fecal
score for the day for each animal. When dogs shared a kennel, a
Assessed for eligibility
n = 1,233 dogs entering the 
shelter between February 2014 
and February 2015
Excluded: n = 430 (403 
stray dogs reclaimed before
kennel allocation and
27 dogs excluded at vet 
examination)
Randomized: n = 803
Allocation to Placebo: 
n = 393
Allocation to Synbiotic:
n = 410
Analyzed: n = 399 (11 dogs 
excluded from analysis as <1 
day feces recorded)
Analyzed: n = 374 (19 dogs 
excluded from analysis as <1 
day feces recorded) 
Fig 1. Flow diagram of dogs through the trial phases.
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single fecal score of the most liquid feces was assigned to both
dogs when defecation was not witnessed. Frequency of defecation
was not recorded because kenneled animals were not under con-
stant supervision. Dogs that had <1 day of fecal scoring were
excluded from analysis because no data were available. Dogs left
the trial if they were adopted, fostered, euthanized, or at the
request of the veterinarian. The dog’s date of entry into the trial,
date of exit from the trial, sex, breed, group allocation, and daily
fecal score all were recorded. The average number of days with
fecal scores recorded for dogs in each group was statistically com-
pared by a Mann-Whitney U-test. A chi-square test was used to
evaluate distribution of sexes to each group which was not statisti-
cally diﬀerent.
Samples of both synbiotic and placebo capsules were removed
from the trial site at the end of the trial and sent to a United
Kingdom Accreditation Services (UKAS)-accredited laboratory for
culture.
The primary outcome measure, the incidence of diarrhea, was
analyzed by comparing the synbiotic and placebo groups’ mean
percentage of days scored as diarrhea out of the total number of
days with fecal scores recorded throughout each dog’s stay by a
Wilcoxon rank sum test. The secondary outcome measure, the
occurrence rate of ≥1 day of diarrhea and ≥2 days of diarrhea by
day 14 of the animal’s stay, was plotted on a Kaplan-Meier sur-
vival curve and analyzed by log rank tests. Statistical analyses
were performed by an independent medical statisticianc by a com-
mercially available software packaged .
A power calculation was performed before the trial. Animal
shelter staﬀ estimated that 30% of the population of dogs experi-
enced at least 1 episode of diarrhea during their stay. To detect a
change in incidence of diarrhea from 30% with the placebo to
20% for the treatment group with a signiﬁcance level of 0.05 and
power of 80%, 582 dogs were required for the triale .
Fecal scores were recorded on each dog’s daily health sheets,
and these sheets could not be collected for analysis until after the
animal had left the shelter. Therefore, it was not possible to count
dogs as they completed the trial. For this reason, a year of recruit-
ment was estimated, based on previous dog intake numbers, to be
suﬃcient to obtain the 582 dogs required by the power
calculation.
Results
A total of 773 dogs completed the trial to analysis.
Figure 1 includes a description of the dogs’ inclusion or
exclusion from the trial. There were 399 dogs with
8,904 days of fecal scores recorded in the synbiotic pro-
duct group and 374 dogs with 8,411 days of fecal scores
recorded in the placebo group (Table 1). Forty-two
dogs entered as part of a pair and shared a kennel; 13
pairs were assigned to the synbiotic group and 8 pairs
to the placebo group. The number of days with a fecal
score recorded for a single dog ranged from 1 to
168 days (median, 16.5 days) for the synbiotic group
and 1–148 days (median, 16 days) for the placebo
group. By a Mann-Whitney U-test to compare the med-
ian number of days with recorded fecal scores, the dis-
tribution of the synbiotic and placebo groups did not
diﬀer signiﬁcantly (Z score, 0.3123; P = .7565)f .
Overall, 55.37%, 428 of 773 dogs were male. The syn-
biotic group was comprised of 53.13%, 212 of 399 male
dogs, and in the placebo group, 57.75%, 216 of 374
dogs were male. The diﬀerence between sexes in groups
was compared by a 2-tailed chi-square test and was
found not to be statistically signiﬁcant (P = .1965)g .
The 7 most common breeds recorded for both groups
were the same, with the 4 most common appearing in
the same order of occurrence: crossbreeds (124 synbiotic
group, 120 placebo group), Staﬀordshire Bull Terriers
(40 synbiotic group, 54 placebo group), Jack Russell
Terriers (39 synbiotic group, 32 placebo group), and
Lurchers (26 synbiotic group, 30 placebo group).
Seven dogs in each group received novel protein diets
for food-related dermatology conditions, whereas 3
dogs in the synbiotic group and 4 in the placebo group
received weight loss diets.
The mean percentage of days scored as diarrhea of
the total number of scored days during each dog’s stay
was 2.0% in the synbiotic group and 3.2% in the pla-
cebo group (P = .0008). Table 1 shows an overview of
each day’s fecal score for dogs in the synbiotic group
and placebo group. Table 2 shows a summary of the
number of dogs with ≥1 day scored as diarrhea
throughout their overall stay at the shelter, and by week
for the ﬁrst 4 weeks.
Kaplan-Meier survival curves were used to compare
the temporal pattern of ﬁrst appearance of diarrhea
between the intervention groups (Fig 2), evaluated by
the log rank test. By day 14, 18.8% of dogs in the syn-
biotic group and 27.2% in the placebo group had
Table 1. Overview of each day’s fecal score for dogs
in the synbiotic group and the placebo group through-
out their shelter stay
Synbiotic
399 Dogs
Placebo
374 Dogs
Total 8904 (100.0%) 8411 (100.0%)
Normal 7872 (88.4%) 7152 (85.0%)
Hard 34 (0.4%) 42 (0.5%)
Soft 820 (9.2%) 959 (11.4%)
Diarrhea 178 (2.0%) 258 (3.1%)
Table 2. : Summary of the number of dogs with
≥1 day scored as diarrhea, throughout their overall stay
at the shelter and by week, for the ﬁrst 4 weeks
Synbiotic Placebo
Overall Number of dogs with data 399 374
Number of dogs with diarrhea 90 123
% 23% 33%
Week 1 Number of dogs with data 399 374
Number of dogs with diarrhea 40 65
% 10% 17%
Week 2 Number of dogs with data 328 304
Number of dogs with diarrhea 32 38
% 10% 13%
Week 3 Number of dogs with data 226 223
Number of dogs with diarrhea 15 26
% 7% 12%
Week 4 Number of dogs with data 147 130
Number of dogs with diarrhea 9 21
% 6% 16%
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experienced at least 1 episode of diarrhea (P = .0022).
By day 14, 4.6% of dogs in the synbiotic group had
experienced diarrhea lasting ≥2 days, compared with
8.0% in the placebo group (P = .0300).
No adverse events or eﬀects were reported in either
intervention group. The UKAS-accredited laboratory
reported the synbiotic capsules to contain
1.58 9 1010 cfu/capsule and placebo capsules <18 cfu/
capsule of bacteria in the Enterococcus genus.
Discussion
The objective of our trial was to test the eﬀects of an
orally administered prophylactic synbiotic supplement
on the incidence of diarrhea in dogs entering an animal
shelter. The results indicated that supplementation with
the synbiotic signiﬁcantly decreased diarrhea incidence
across all 3 measures in the trial. The ﬁrst measure of
incidence used mean percentage of days per dog that
were scored as diarrhea throughout their stay instead of
the overall group percentage of days scored as diarrhea.
This approach was used to prevent data from being
skewed in the case of a few long-stay animals with per-
sistent diarrhea being assigned to the same group. Sur-
vival analysis, a collection of statistical procedures for
data analysis in which the outcome variable of interest
is time until an event occurs,19 was used for the remain-
ing 2 measures of diarrhea incidence. Fourteen days
was chosen before commencing the trial as the time
point for Kaplan-Meier survival analysis because it was
the median number of days stay at the shelter in the
year preceding data collection. Sixteen was the median
number of days stay at the shelter for our sample.
Kaplan-Meier survival analysis method was used to
compare the percentage of dogs that had experienced at
least 1 episode of diarrhea in each group within the ﬁrst
14 days. The percentage of dogs in each group that had
had diarrhea lasting ≥2 days by day 14 also was com-
pared. This number was of interest because when diar-
rhea lasted ≥2 consecutive days, the dogs would be
scheduled for a veterinary evaluation and treatment
would be prescribed.
A trial that used the probiotic species Biﬁdobacterium
animalis, which is commercially available in the United
States of America, also found that signiﬁcantly fewer
probiotic-supplemented dogs passed unacceptable feces
(loose or diarrheic) during the ﬁrst week of relocation,
and during their overall stay at a kennel facility, when
compared to controls.9 This trial randomized 134 young
Labrador Retrievers or Labrador-Golden Retrievers to
4 groups: 3 diﬀerent doses of probiotic and a control
group. The dogs in the Biﬁdobacterium animalis study
began their probiotic supplementation 5 weeks before
entering the kennels. Enterococcus faecium was selected
for the current trial because it currently is the only pro-
biotic species licensed in the European Union for
dogs.20 The population of dogs in our study was a mix
of ages and breeds, typical of a shelter in the United
Kingdom, and were not supplemented before kenneling
because it was not realistic for dogs entering an animal
shelter. It would be interesting to investigate the eﬀect
of synbiotic supplementation in other stressful situa-
tions, such as competitions and planned holiday kennel-
ing, to assess the eﬃcacy of the product in these
scenarios.
A previously performed trial using the probiotic spe-
cies Enterococcus faecium on dogs in an animal shelter
did not ﬁnd statistical signiﬁcance to support the
hypothesis that the probiotic would decrease the inci-
dence of diarrhea of ≥2 days’ duration compared with
placebo.10 This trial had a very low incidence of diar-
rhea lasting ≥2 days (2 dogs in a study population of
182), which was unexpected and possibly a result of
short-stay durations, a consistent diet for all kenneled
dogs and lack of stress due to the kenneling facilities.
We found a statistically signiﬁcant eﬀect of Enterococ-
cus faecium in our trial, using the same outcome mea-
sure (incidence of diarrhea ≥2 days’ duration), in an
adequately powered study with a higher incidence of
diarrhea. When the same trial was performed in cats,
where the incidence of diarrhea ≥2 days’ duration in the
placebo group was higher (20.7%), a statistically signiﬁ-
cant decrease in diarrhea ≥2 days’ duration was found
in the probiotic group (7.4%; P = .0297).10
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Fig 2. Plot of Kaplan-Meier Estimate of time to ﬁrst diarrhea. Dogs with ≥1 day’s data.
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Limitations to our trial include a lack of medical his-
tory for the majority of animals because of the nature
of being an animal shelter. This may mean that a pre-
disposition to diarrhea was more prevalent in certain
individuals. We believe that this eﬀect was minimized
by the randomization process and large sample size.
Age was not recorded because of a lack of information
given about dogs entering the shelter. Previously,
females have been found to have lower odds of develop-
ing diarrhea compared with males.2 There were more
males than females in our trial, but this diﬀerence was
not statistically signiﬁcant (P = .1965). Diet was not
kept constant throughout the trial for all dogs, which
could have played a role in the development of diar-
rhea, but this was meant to reﬂect normal working
practice for animal shelters, the majority of which rely
on donations to feed their dogs. Again, the large sample
size and randomization process should have minimized
the eﬀect on our trial. Forty-two dogs were housed as
pairs in our trial and assigned to the same group to
decrease the risk of treatment contamination. Given
that our trial was carried out in a working animal shel-
ter, it was not possible to alter normal working prac-
tices. One hundred and ninety-one more dogs
completed the trial than required by the power calcula-
tion (582), and this overage was caused by a speciﬁc
date as an endpoint rather than counting dogs, which
was a more practical solution in a working shelter.
A simple 4-category fecal scoring system (hard, nor-
mal, soft, diarrhea) was created for our trial, adapted
from the Nestle Purina and Waltham feces scoring sys-
temsh ,i after staﬀ at the animal shelter expressed con-
cerns over the complexity of the original systems. All
staﬀ received training in the 4-category fecal scoring
system and posters were placed in all dog kitchens and
admission rooms as a prompt. Fecal scoring is subjec-
tive and there is likely to be some intra-observer and
interobserver variability despite having descriptors and
representative picture available, but there is evidence to
suggest fecal scoring is superior to measuring fecal
moisture content and fecal dry matter.21,22
Animals with a known history of chronic or recurrent
diarrhea or abnormalities on clinical examination were
excluded from the trial. Therefore, conclusions can only
be made about healthy animals entering an animal shel-
ter. It is also not possible to draw any conclusions
regarding the eﬃcacy of other potential probiotic
strains or prebiotics beyond those used in our trial.
Samples of both capsules were cultured at the end of
the trial to ensure that no cross-contamination of the
placebo occurred during manufacture or storage, but
also to ensure the active capsule contained at least the
speciﬁcation declared on the commercial product,
2 9 109 cfu/capsule. The excess quantity of probiotic
was due to overage added by the manufacturer in order
to guarantee live bacteria numbers at the end of a 2-
year shelf life.
In conclusion, the results of our trial support the
hypothesis that supplementing dogs entering an animal
shelter with a synbiotic decreases the incidence of diar-
rhea and provides evidence of the beneﬁcial eﬀect of the
prophylactic use of this synbiotic supplement.
Decreased diarrhea rates would directly improve the
welfare of the dogs and decrease the associated costs of
cleaning, treating, and extended stays in animal shelters.
The results from our study could be included in a cost-
beneﬁt analysis to establish the net cost of routinely
supplementing dogs entering a shelter. There may be an
advantage to the use of this synbiotic preparation in
decreasing diarrhea triggered by other stressful events
such as holiday kenneling and during competitions, but
this hypothesis is yet to be tested.
Footnotes
a Sealed Envelope Ltd. 2012. Power calculator for binary outcome
superiority trial. [Online] Available from: https://www.sealeden
velope.com/power/binary-superiority/ [Accessed Apr 26 2016]
b Synbiotic D-C, Protexin Veterinary, Probiotics International
Ltd., Lopen Head, Somerset, UK
c Wilkinson Associates, Medical Statistics, Radnage, Bucks, UK
d SAS Software release 9.3, SAS Institute Inc., Cary, NC
e Sealed Envelope Ltd. 2012. Power calculator for binary outcome
superiority trial. [Online] Available from: https://www.sealeden
velope.com/power/binary-superiority/ [Accessed Dec 10 2013]
f Social Science Statistics. Mann Whitney U test calculator.
[Online] Available from: http://www.socscistatistics.com/tests/ma
nnwhitney/Default2.aspx [Accessed Nov 24 2016]
g GraphPad Software Inc. 2016. QuickCalcs. [Online] Available
from: https://www.graphpad.com/quickcalcs/ [Accessed Nov 24
2016]
h Nestle Purina Feces Scoring System. Available from: https://
www.purinaproplanvets.com/media/1202/gi_quick_refer-
ence_guide.pdf
i The Waltham Feces Scoring System. Available from: https://
www.waltham.com/dyn/_assets/_pdfs/resources/FaecesQuality2.
pdf
Acknowledgments
The authors thank all staﬀ at Wood Green, The Ani-
mals Charity, Godmanchester, for their work on this
trial. This trial was conducted under the University of
Cambridge, Department of Veterinary Medicine, Cam-
bridge Clinical Research Outreach Program. Thanks
also to Protexin Veterinary for manufacturing and
donating both the active product and placebo product.
Conﬂict of Interest Declaration: Lindsay Rose is an
employee of Probiotics International Ltd. Jeremy Hugh
Rose is married to Lindsay Rose. A donation was given
to Wood Green, The Animals Charity, Godmanchester,
by Probiotics International Ltd. after the trial had been
completed.
Conﬂict of interest was managed by a randomized,
double-blind, placebo-controlled study design. Case
recruitment, data collection, data input, and statistical
analysis were performed by persons independent of Pro-
biotics International Ltd.
Oﬀ-label Antimicrobial Declaration: Authors declare
no oﬀ-label use of antimicrobials.
Synbiotic Eﬀect on Shelter Dog Diarrhea 381
References
1. Hall E. Canine diarrhoea: A rational approach to diagnostic
and therapeutic dilemmas. In Pract 2009;31:8–16.
2. Stavisky J, Radford AD, Gaskell R, et al. A case-control
study of pathogen and lifestyle risk factors for diarrhoea in dogs.
Prev Vet Med 2011;99:185–192.
3. Mertens P, Unshelm J. Veterinary surveillance in animal
shelters–defects and potentials. Dtsch tier€arztliche Wochenschrift
1994;101:232–237.
4. World Health Organization: Food and Agriculture Organiza-
tion of the United Nations. Health and Nutritional Properties of
Probiotics in Food including Powder Milk with Live Lactic Acid
Bacteria. In: Report of a Joint FAO/WHO Expert Consultation
on Evaluation of Health and Nutritional Properties of Probiotics
in Food Including Powder Milk with Live Lactic Acid Bacteria.
2001. p. 1–34.
5. Hill C, Guarner F, Reid G, et al. The International Scientiﬁc
Association for Probiotics and Prebiotics consensus statement on
the scope and appropriate use of the term probiotic. Nat Rev Gas-
troenterol Hepatol 2014;11:506–514.
6. Gibson GR, Probert HM, Van Loo J, et al. Dietary modula-
tion of the human colonic microbiota: Updating the concept of
prebiotics. Nutr Res Rev 2004;17:259–275.
7. Bermudez-Brito M, Plaza-Dıaz J, Mu~noz-Quezada S, et al.
Probiotic mechanisms of action. Ann Nutr Metab 2012;61:160–174.
8. World Health Organization: Food and Agriculture Organiza-
tion of the United Nations. Probiotics in food health and nutri-
tional properties and guidelines for evaluation. FAO Food Nutr
Pap 2006;85:1–50.
9. Kelley R, Levy K, Mundell P, Hayek MG. Eﬀects of varying
doses of a probiotic supplement fed to healthy dogs undergoing
kenneling stress. Int J Appl Res Vet Med 2012;10:205–216.
10. Bybee SN, Scorza AV, Lappin MR. Eﬀect of the probiotic
Enterococcus faecium SF68 on presence of diarrhea in cats and
dogs housed in an animal shelter. J Vet Intern Med 2011;25:856–
860.
11. Chandler M. Probiotics and their validity in small animal
patient therapy. VN Times 2015;15:8–10.
12. Bovens C. Therapeutics in canine GI disorders: Part two –
treatment of diarrhoea. Vet Times 2013;43:10–13.
13. Chandler M. Probiotics in dogs and cats. Vet Times
2016;43:10–11.
14. Basu C, Holding E. Food for thought in evidence base for
nutraceuticals. Vet Times 2014;44:12–13.
15. Matthewman L, Allenspach K. Pre and probiotics - Practi-
cal applications for VNs in practice. VN Times 2013;13:8–9.
16. Schmitz S, Suchodolski J. Understanding the canine intesti-
nal microbiota and its modiﬁcation by pro-, pre- and synbiotics -
what is the evidence? Vet Med Sci 2016;2:71–94.
17. Chandler M. Probiotics - not all created equally. J Small
Anim Pract 2014;55:439–441.
18. Cosgrove L, McLauchlan G. Probiotic use in dogs and cats
– issues and studies into beneﬁts. Vet Times 2014;44:10–12.
19. Kleinbaum D, Klein M. Survival Analysis: A Self-Learning
Text. New York, USA: Springer Science & Business Media; 2006.
20. Regulation (EC) No 1831/2003. European Union Register
of Feed Additives. Annex I. 2016; (Edition 236).
21. Sunvold GD, Fahey GC, Merchen NR, et al. Dietary ﬁber
for dogs: IV. In vitro fermentation of selected ﬁber sources by dog
fecal inoculum and in vivo digestion and metabolism of ﬁber-sup-
plemented diets. J Anim Sci 1995;73:1099–1109.
22. Nery J, Biourge V, Tournier C, et al. Inﬂuence of dietary
protein content and source on fecal quality, electrolyte concentra-
tions, and osmolarity, and digestibility in dogs diﬀering in body
size. J Anim Sci 2010;88:159–169.
382 Rose et al
